Skip to main navigation Skip to search Skip to main content

History of thyroid disease and survival of ovarian cancer patients: Results from the Ovarian Cancer Association Consortium, a brief report

  • Albina N. Minlikeeva
  • , Jo L. Freudenheim
  • , Rikki A. Cannioto
  • , Kevin H. Eng
  • , J. Brian Szender
  • , Paul Mayor
  • , John L. Etter
  • , Daniel W. Cramer
  • , Brenda Diergaarde
  • , Jennifer A. Doherty
  • , Thilo Dörk
  • , Robert Edwards
  • , Anna Defazio
  • , Grace Friel
  • , Marc T. Goodman
  • , Peter Hillemanns
  • , Estrid Høgdall
  • , Allan Jensen
  • , Susan J. Jordan
  • , Beth Y. Karlan
  • Susanne K. Kjær, Rüdiger Klapdor, Keitaro Matsuo, Mika Mizuno, Christina M. Nagle, Kunle Odunsi, Lisa Paddock, Mary Anne Rossing, Joellen M. Schildkraut, Barbara Schmalfeldt, Brahm H. Segal, Kristen Starbuck, Kathryn L. Terry, Penelope M. Webb, Emese Zsiros, Roberta B. Ness, Francesmary Modugno, Elisa V. Bandera, Jenny Chang-Claude, Kirsten B. Moysich
  • Roswell Park Cancer Institute
  • Brigham and Women’s Hospital
  • University of Pittsburgh
  • Dartmouth College
  • Hannover Medical School
  • The University of Sydney
  • Cedars-Sinai Medical Center
  • Danish Cancer Society
  • University of Copenhagen
  • Queensland Institute of Medical Research
  • Aichi Cancer Center Hospital and Research Institute
  • University of Queensland
  • State of New Jersey
  • Rutgers - The State University of New Jersey, New Brunswick
  • Fred Hutchinson Cancer Research Center
  • University of Virginia
  • University of Hamburg
  • University of Texas Health Science Center at Houston
  • German Cancer Research Center

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Abstract

Background:Findings from in vitro studies suggest that increased exposure to thyroid hormones can influence progression of ovarian tumours. However, epidemiologic evidence on this topic is limited.Methods:We pooled data from 11 studies from the Ovarian Cancer Association Consortium. Using multivariate Cox proportional hazards models, we estimated associations between hyper-and hypothyroidism and medications prescribed for these conditions with 5-year all-cause survival among women diagnosed with invasive ovarian cancer.Results:Overall, there was a nonsignificant association with history of hyperthyroidism (n=160 cases) and mortality (HR=1.22; 95% CI=0.97-1.53). Furthermore, diagnosis of hyperthyroidism within the 5 years before ovarian cancer diagnosis was associated with an increased risk of death (HR=1.94; 95% CI=1.19-3.18). A more modest association was observed with history of hypothyroidism (n=624 cases) and mortality (HR=1.16; 95% CI=1.03-1.31). Neither duration of hypothyroidism nor use of thyroid medications was associated with survival.Conclusions:In this large study of women with ovarian cancer, we found that recent history of hyperthyroidism and overall history of hypothyroidism were associated with worse 5-year survival.

Original languageEnglish
Pages (from-to)1063-1069
Number of pages7
JournalBritish Journal of Cancer
Volume117
Issue number7
DOIs
StatePublished - Sep 26 2017

Keywords

  • hyperthyroidism
  • hypothyroidism
  • ovarian cancer
  • prognosis
  • survival

Fingerprint

Dive into the research topics of 'History of thyroid disease and survival of ovarian cancer patients: Results from the Ovarian Cancer Association Consortium, a brief report'. Together they form a unique fingerprint.

Cite this